Gladiators of Safety and Efficacy: CRISPR QC Provides Third-Party Validation in Gene Editing

CRISPR technology has not yet been FDA approved for Cystic Fibrosis or Muscular Dystrophy and is still being investigated for use against these diseases.

Gene editing has enormous potential to address some of the most pressing global challenges in healthcare, agriculture and beyond. Its potential to correct genetic and cancer-causing mutations is genuinely revolutionary. It can also be used in therapies to target cystic fibrosis, and muscular dystrophy as well as develop customized treatments for individualized genetic make-up. Likewise, gene editing can be used to advance agricultural products to adapt to problems caused by climate change. It even enables the modification of microorganisms for the production of biofuels, pharmaceuticals, enzymes and other valuable products. It’s pretty cool science.

With all this amazing potential, why the controversy?

Gene editing raises ethical and social issues for some and there are safety considerations that must be carefully navigated to ensure responsible and equitable deployment of this technology. Founder Ross Bundy of CRISPR QC, a company that offers quality assurance and risk management in gene editing, asserts, “Independent third-party validators are paramount.” These entities serve as gladiators of safety and efficacy by offering reassurance to all stakeholders.

The history of gene therapy

In the late nineties, exciting advancements in gene editing were being made. “Researchers discovered they could insert DNA to cure people of different genetic diseases. The technology moved very rapidly, and in 2000, they did a clinical trial on humans. The trial was aimed at combating a devastating genetic disease in children, but it ended catastrophically.” Jesse Gelsinger, a participant in the trial, suffered a severe adverse reaction to the treatment and died shortly after receiving it. “The unintended consequences of those trials included some participants developing cancer, and there was a fatality,” Bundy explains. “The incident raised serious concerns about the safety and oversight of gene therapy research.” Gene editing’s momentum came to a screeching halt.

Out of that situation came an intrinsic fear surrounding gene editing. “There is this paradigm that DNA, the blueprint of life, is immutable once altered. It can’t be changed back. Even though gene editing has huge potential, patients grapple with the uncertainty of outcomes and the potential for unforeseen consequences. Unlike traditional pharmaceutical interventions, like a pill or medication, genetic therapies leave no room for error, so it truly intensifies the stakes for both patients and practitioners.”

Third-party validation is key

Bundy notes that with third-party validation, it will be easier for people to trust the outcomes of genetic therapies. “This lack of trust can deter individuals from pursuing potentially beneficial life-changing therapies. It limits their willingness to embrace innovation in healthcare. The absence of validation, ultimately, creates a barrier for patients.”

Companies serious about creating trust and buy-in should take a proactive approach to validating their solutions. “It not only fosters confidence in therapeutic outcomes but also mitigates financial liabilities for insurers and healthcare providers as well.”

He explains, “The complexity of the science and the fear of irreversible consequences make patients hesitant. They weigh the unknown benefits against the potential risks, often choosing the familiar status quo over uncertain outcomes. This hesitancy poses a significant barrier to adopting new treatments, as patients prioritize their current condition and well-being over the possibility of worsening their situation. Without third-party validation, people will struggle to trust genetic therapies.”

De-risking gene editing

Fortunately, companies like CRISPR QC are helping de-risk gene editing. By providing rigorous validation and quality control solutions, they enable researchers to overcome the complexities of genetic manipulation and take the risks out of their solutions. CRISPR QC helps companies enhance safety in gene editing.

Bundy emphasizes that the exorbitant costs associated with healthcare magnify the need for assurances regarding treatment outcomes. If a treatment costs millions of dollars per patient, insurance companies have to weigh the risks. By providing robust data on gene editing activity, CRISPR QC gives insurers the assurances they need and makes the therapies more economically viable.

The essential role of third-party validation

“Overall, third-party validation fosters trust, promotes accountability, and mitigates risks, thereby driving innovation and progress across diverse sectors. That is what we do, what CRISPR QC can do for gene editing,” Bundy explains. “Having a third party come in and be a technical expert for those who don’t have the expertise moves this industry forward. Patients feel safer about these novel treatment options, and companies with impactful solutions get more patients who are open to treatment. That is where CRISPR QC can really bring value for companies.”

Gene editing holds tremendous promise in revolutionizing healthcare, agriculture, and beyond. It offers potential solutions for genetic diseases, cancer, climate-resistant crops and even biofuel production. As gene editing continues to advance, third-party validators like CRISPR QC play a crucial role in ensuring the reliability and safety, and ultimately, the advancement of genetic therapies.

The information in this article is for informational purposes only.  Please consult a medical professional regarding any specific health concerns.